How we manage follicular lymphoma

Leukemia

Volumn 28, Issue 7, 2014, Pages 1388-1395

  Hiddemann, W ^a   Cheson, B D ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; EPRATUZUMAB; EVEROLIMUS; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LUMILIXIMAB; NAVITOCLAX; OBINUTUZUMAB; RITUXIMAB; TEMSIROLIMUS; VENETOCLAX;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION;

HUMANS; LYMPHOMA, FOLLICULAR; NEOPLASM STAGING;

EID: 84904053333     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.91     Document Type: Article

References (111)

1. National Cancer Institute. SEER Cancer Statistics Review. NIH Bethesda, Maryland, USA, 2008 23.
2. Anderson JR, Armitage JO, Weissenburger DD. Epidemiology of the non-Hodgkin? s lymphomas distribution of the major subtypes differ by geographic locations. Non-Hodgkin? s Lymphoma Classification Project. Ann Oncol 1998 7 717-720.
3. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012 122 3424-3431.
4. Stevenson FK, Stevenson GT. Follicular lymphoma and the immune system from pathogenesis to antibody therapy. Blood 2012 119 3659-3667.
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. WHO Geneva, Siwtzerland, 2008.
6. Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Dis 2012 2 47-55.
7. Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood 2012 120 2553-2561.
8. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN Clinical Practice Guidelines in Oncology non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010 8 288-334.
9. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1 diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL). Ann Oncol 2013 24 561-576.
10. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996 14 1282-1290.
11. Stuschke M, Hoederath A, Sack H, Po? tter R, Mu? ller RP, Schulz U et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas results of a prospective multicenter study. Study Group NHL-fru?he Stadien. Cancer 1997 80 2273-2284.
12. Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001 51 1219-1227.
13. Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006 64 928-934.
14. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation a surveillance, epidemiology, and end results database analysis. Cancer 2010 116 3843-3851.
15. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010 116 3797-3806.
16. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma a randomised phase III trial. Radiother Oncol 2011 100 86-92.
17. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J et al. Effectiveness of first-line management strategies for stage I follicular lymphoma analysis of the National LymphoCare Study. J Clin Oncol 2012 30 3368-3375.
18. Wennekes L, Ottevanger PB, Raemaekers JM, Schouten HC, de Kok MW, Punt CJ et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma. J Clin Oncol 2011 29 1436-1444.
19. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma long-term follow-up of no initial therapy. J Clin Oncol 2004 22 1454-1459.
20. Ruella M, Filippi A, Di Russo A, Caracciolo D, Matteucci P, Magni M et al. Rituximab followed by involved field radiotherapy (IF-RT) in stage I-II follicular lymphoma (FL) long term results. Blood (ASH Annual Meeting Abstracts) 2011 118 a3699.
21. Herfarth K, Engelhard M, Borchmann P, Hohloch K, Budach V, Viardot A et al. Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab preliminary results of the MIR trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG). Blood (ASH Annual Meeting Abstracts) 2012 120 a1634.
22. Brice P, Bastion Y, Lepage E, Brousse N, Haoun C, Moreau P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997 15 1110-1117.
23. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma a randomised controlled trial. Lancet 2003 362 516-522.
24. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010 28 4480-4484.
25. Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma survival analyses with 7-year follow-up. Ann Oncol 2012 23 2380-2385.
26. Ardeshna K, Qian W, Smith P, Warden J, Stevens L, Pocock CFE et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010 116 a6.
27. Ardeshna K, Qian W, Stephens R, Smith P, Warden J, Lowry L et al. Preliminary results of quality of life analyses from the Intergroup phase III randomized trial of rituximab vs. a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol 2011 22(Suppl. 4) a019.
28. Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC et al. Results of the Eastern Cooperative Oncology Group protocol E 4402 (RESORT) A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011 118 LBA6.
29. Solal-Ce? ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era results of an F2-study database. J Clin Oncol 2012 30 848-853.
30. Cheson BD. Waiting is the hardest part. J Clin Oncol 2012 30 3781-3782.
31. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 106 3725-3732.
32. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005 105 1417-1423.
33. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007 25 1986-1992.
34. Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients results of the GELA-GOELAMS FL2000 study. Blood 2008 112 4824-4831.
35. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 26 4579-4586.
36. Morschhauser F, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Bouabadallah R et al. Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011 22(suppl 4) 488.
37. Federico M, Luminari S, Dondi A, Sacchi S, Tucci A, Vitolo U et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL). J Clin Oncol 2013 31 1506-1513.
38. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gru? nhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas an openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013 381 1203-1210.
39. Flinn IW, Van der Jagt RH, Kahl BS, Wood P, Hawkins TE et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL) the Bright study. Blood 2012 120 a 902.
40. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005 352 441-449.
41. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006 24 4143-4149.
42. Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008 14 7088-7094.
43. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010 28 3035-3041.
44. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008 26 5156-5164.
45. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma SWOG S0016. J Clin Oncol 2013 31 314-320.
46. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004 104 2667-2674.
47. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma a randomized multicenter study by GOELAMS. Blood 2005 105 3817-3823.
48. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006 108 2540-2544.
49. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008 111 4004-4013.
50. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma a systematic review and meta-analysis. J Natl Cancer Inst 2012 104 18-28.
51. Hiddemann W, Dreyling MH, Metzner B, Pfreundschuh M, Wilhelm M et al. Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial immuno-chemotherapy (R-CHOP) or chemotherapy alone analysis of 940 patients treated in prospective randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 2013 223 a419.
52. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission long-term follow-up. J Clin Oncol 2007 25 2554-2559.
53. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma a GELA study. J Clin Oncol 2008 26 3614-3620.
54. Weigert O, Uysal A, Metzner B, Pfreundschuh M, Schmitz N, Wandt H et al. Impact of autologous stem cell transplantation and/or rituximab on outcome of patients with relapsed follicular lymphoma-retrospective analysis of 2 randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 2008 112 a 2189.
55. Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 2011 96 1128-1135.
56. Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG et al. Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma potential benefit in second relapse. Haematologica 2013 98 620-625.
57. Hainsworth JD, Litchy S, Burris 3rd HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002 20 4261-4267.
58. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004 103 4416-4423.
59. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction results of a prospective randomized phase 3 intergroup trial. Blood 2006 108 3295-3301.
60. Forstpointner R, Unterhalt M, Dreyling M, Bo? ck HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 108 4003-4008.
61. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009 27 1607-1614.
62. Salles G, Seymour JF, Offner F, Lo? pez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) a phase 3, randomised controlled trial. Lancet 2011 377 42-51.
63. Salles G, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 2013 223 a509.
64. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005 23 1088-1095.
65. Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 2013 31 3351-3359.
66. Cheson BD. New agents in follicular lymphoma. Best Pract Res Clin Haematol 2011 24 305-312.
67. Younes A. Beyond chemotherapy new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011 8 85-96.
68. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma results of a phase 1/2 trial. Blood 2008 111 5486-5495.
69. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma results from a multicenter study. Blood 2012 119 3698-3704.
70. Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012 119 5118-5125.
71. Salles G, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H et al. Obinutuzumab (GA 101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma results from the phase II GAUGIN study. J Clin Oncol 2013 31 2920-2926.
72. Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R et al. Obinutuzumab (GA 101) plus CHOP or FC in relapsed/refractory follicular lymphoma results of the GAUDI study (BO21000). Blood 2013 122 1137-1143.
73. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006 24 3880-3886.
74. Grant BW, Jung SH, Johnson JL, Kostakoglu L, His E, Byrd JC et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma CALGB 50701. Cancer 2013 119 3797-3804.
75. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma results of a phase I study. J Clin Oncol 2010 28 2085-2093.
76. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013 31 573-583.
77. Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402) Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol 2012 23 2356-2362.
78. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008 321 974-977.
79. Nagorsen D, Zugmaier G, Viardot A, Goebeler M, Noppeney R, Schmidt M et al. Confirmation of safety, efficacy and response duration in non-Hodgkin lymphoma patients treated with 60 mg/m2/d of BiTEs antibody Blinatumomab. Blood 2009 114 a 2723.
80. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009 27 3822-3829.
81. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes the University of Chicago phase II consortium. J Clin Oncol 2010 28 4740-4746.
82. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukaemia 2011 25 341-347.
83. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL et al. PI3Kd inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012 119 1897-1900.
84. Gopal A, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood 2013 223 a85.
85. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Blood 2010 115 2578-2585.
86. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013 31 88-94.
87. Kahl B, Roberts AW, Seymour JF, Advani RH, Persky DO, Yang J et al. Navitoclax (ABT-263) plus rituximab Interim results of a phase I study in patients with CD 20-positive lymphoid malignancies. Blood 2010 116 a3943.
88. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The bcl2 specific BH3-mimetic ABT-199 (GDC-0199) is active and well tolerated in patients with relapsed non-Hodgkin lymphoma interim results of a phase I study. Blood 2012 120 a304.
89. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008 26 1544-1552.
90. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009 27 5404-5409.
91. Dutia M, DeRoock I, Chee K, O'donnell R, Quirch C, Reed-Pease C et al. R2 Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL). Blood 2009 114 a 1679.
92. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE et al. Lenalidomide and rituximab for untreated indolent lymphoma final results of a phase II study. Blood 2012 120 a 901.
93. Solal-Ce?ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004 104 1258-1265.
94. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006 108 1504-1508.
95. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al. Follicular lymphoma international prognostic index 2 a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009 27 4555-4562.
96. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004 351 2159-2169.
97. Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005 105 301-307.
98. Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, Do? hner H et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009 48 39-54.
99. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010 115 289-295.
100. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011 29 3194-3200.
101. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 2012 30 4317-4322.
102. Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2014 25 442-447.
103. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 25 579-586.
104. Pott C, Bru?ggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol 2013 971 175-200.
105. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999 94 3325-3333.
106. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002 99 856-862.
107. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programme. Blood 2013 122 3759-3766.
108. Hirt C, Schu? ler F, Kiefer T, Schwenke C, Haas A, Niederwieser D et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab clinical significance of quantitative t(1418) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol 2008 141 631-640.
109. Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003 14 758-765.
110. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009 43 701-708.
111. Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 2012 23 2687-2695.